All In Biotech

Drug Trial Radar · NCT02588612

Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

A Pilot Open-Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)

Last checked: Nov 20, 2026Latest source record: Sep 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

10

Actual

Start

Feb 1, 2016

Primary completion

Aug 10, 2020

Study completion Aug 10, 2020

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Oct 28, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will evaluate safety and efficacy of letetresgene autoleucel (GSK3377794) in participants with metastatic NSCLC.

Conditions

  • Neoplasms

Interventions

  • letetresgene autoleucel (GSK3377794)Drug

    letetresgene autoleucel (GSK3377794) as an IV infusion.

  • CyclophosphamideDrug

    Cyclophosphamide will be used as a lymphodepleting chemotherapy.

  • FludarabineDrug

    Fludarabine will be used as a lymphodepleting chemotherapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 24 months
  2. Number of Participants With Hematology Results by Maximum Grade Increase Post-BaselineTime frame: Up to 24 months
  3. Number of Participants With Any Grade Increase in Clinical Chemistry ParametersTime frame: Up to 24 months
  4. Number of Participants With Worst Case Post-Baseline Abnormal Electrocardiogram (ECG) FindingsTime frame: Up to 24 months
  5. Change From Baseline in Oxygen SaturationTime frame: Baseline, Day 1 (pre-dose, 5, 15, and 30 minutes, 1, 1.5, 2, and 4 hours post dose), Days 2, 3, 4, 5, 8 and Week 2

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Miami, Florida

  • GSK Investigational Site

    Tampa, Florida

  • GSK Investigational Site

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.